Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...